The global postmenopausal osteoporosis treatment market accounted for USD 9.65 billion in 2023 and is expected to reach at USD 17.04 billion by 2034 with a CAGR of 5.31% during the forecast period 2024-2034. The rising elderly population, increased awareness and early diagnosis, advancements in treatment choices, emphasis on preventative measures, expanding government initiatives, and increasing strategic collaborations and partnerships will all fuel market expansion.
The healthcare industry is constantly innovating and creating novel treatments for osteoporosis. This includes the introduction of biopharmaceuticals, which are targeted medicines with superior efficacy and tolerance compared to conventional medications. For instance, in August 2022, Myovant Sciences and Pfizer announced that MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) was approved by the US Food and Drug Administration (FDA) as a once-daily, one-pill treatment for the management of moderate to severe endometriosis pain in premenopausal women, with a maximum 24-month treatment period.
By drug type, the bisphosphonates segment accounted for the highest revenue-grossing segment in the global postmenopausal osteoporosis treatment market in 2023 owing to the efficacy of bisphosphonates in reducing fracture risk, widespread availability, and established use as first-line treatment options for postmenopausal osteoporosis. For instance, in September 2023, Sanofi announced the completion of its acquisition of Qunol, a US-based health and wellness market leader. Additionally, the hormone replacement therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of hormone replacement therapy's benefits in managing osteoporosis symptoms, advancements in hormone formulations, and increasing acceptance of bioidentical hormones among postmenopausal women.
By distribution channel, the retail pharmacy segment accounted for the highest revenue-grossing segment in the global postmenopausal osteoporosis treatment market in 2023 owing to the convenience of access, wide availability of osteoporosis medications, and increasing preference for retail pharmacies among patients for prescription fulfillment and counseling services. For instance, in July 2022, Chugai Pharma China Co., Ltd., a subsidiary of Chugai Pharmaceutical Co., Ltd., debuted Edirol (eldecalcitol) in China after getting permission from the China National Medical Products Administration (NMPA) to treat postmenopausal osteoporosis. Edirol is an active vitamin D3 derivative developed by Chugai. Additionally, the online pharmacy segment is predicted to grow at the fastest CAGR during the forecast period owing to the convenience, accessibility, and growing preference for online shopping, coupled with advancements in e-commerce technology and increasing digitalization of healthcare services.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of postmenopausal osteoporosis, well-established healthcare infrastructure, increasing awareness about bone health, and favorable reimbursement policies for osteoporosis treatments in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly aging population, rising healthcare expenditure, improving access to healthcare services, increasing awareness about osteoporosis, and growing adoption of preventive healthcare measures in the Asia Pacific region. For instance, in November 2023, Eli Lilly and Company announced that it would invest $2.5 billion (2.3 billion euros) in the construction of a new high-tech manufacturing plant in Alzey, Rhineland-Palatinate. The company also intends to invest up to $100 million in Germany's start-up ecosystem for life science and biotech companies.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
The healthcare industry is constantly innovating and creating novel treatments for osteoporosis. This includes the introduction of biopharmaceuticals, which are targeted medicines with superior efficacy and tolerance compared to conventional medications. For instance, in August 2022, Myovant Sciences and Pfizer announced that MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) was approved by the US Food and Drug Administration (FDA) as a once-daily, one-pill treatment for the management of moderate to severe endometriosis pain in premenopausal women, with a maximum 24-month treatment period.
By drug type, the bisphosphonates segment accounted for the highest revenue-grossing segment in the global postmenopausal osteoporosis treatment market in 2023 owing to the efficacy of bisphosphonates in reducing fracture risk, widespread availability, and established use as first-line treatment options for postmenopausal osteoporosis. For instance, in September 2023, Sanofi announced the completion of its acquisition of Qunol, a US-based health and wellness market leader. Additionally, the hormone replacement therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of hormone replacement therapy's benefits in managing osteoporosis symptoms, advancements in hormone formulations, and increasing acceptance of bioidentical hormones among postmenopausal women.
By distribution channel, the retail pharmacy segment accounted for the highest revenue-grossing segment in the global postmenopausal osteoporosis treatment market in 2023 owing to the convenience of access, wide availability of osteoporosis medications, and increasing preference for retail pharmacies among patients for prescription fulfillment and counseling services. For instance, in July 2022, Chugai Pharma China Co., Ltd., a subsidiary of Chugai Pharmaceutical Co., Ltd., debuted Edirol (eldecalcitol) in China after getting permission from the China National Medical Products Administration (NMPA) to treat postmenopausal osteoporosis. Edirol is an active vitamin D3 derivative developed by Chugai. Additionally, the online pharmacy segment is predicted to grow at the fastest CAGR during the forecast period owing to the convenience, accessibility, and growing preference for online shopping, coupled with advancements in e-commerce technology and increasing digitalization of healthcare services.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of postmenopausal osteoporosis, well-established healthcare infrastructure, increasing awareness about bone health, and favorable reimbursement policies for osteoporosis treatments in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly aging population, rising healthcare expenditure, improving access to healthcare services, increasing awareness about osteoporosis, and growing adoption of preventive healthcare measures in the Asia Pacific region. For instance, in November 2023, Eli Lilly and Company announced that it would invest $2.5 billion (2.3 billion euros) in the construction of a new high-tech manufacturing plant in Alzey, Rhineland-Palatinate. The company also intends to invest up to $100 million in Germany's start-up ecosystem for life science and biotech companies.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
Study Coverage
- Market Forecast by Drug Type, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Postmenopausal Osteoporosis Treatment Market Report 2023 - 2034
Postmenopausal Osteoporosis Treatment Market Analysis & Forecast by Drug Type 2023 - 2034 (Revenue USD Bn)
- Bisphosphonates
- Vitamin D3
- Estrogen Agonist/Antagonist
- Hormone Replacement Therapy
- Parathyroid Hormone Therapy
- Others
Postmenopausal Osteoporosis Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Postmenopausal Osteoporosis Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Postmenopausal Osteoporosis Treatment Market: Drug Type Estimates & Trend Analysis
8. Postmenopausal Osteoporosis Treatment Market: Distribution Channel Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Postmenopausal Osteoporosis Treatment Market
11. Europe Postmenopausal Osteoporosis Treatment Market
12. Asia Pacific Postmenopausal Osteoporosis Treatment Market
13. Latin America Postmenopausal Osteoporosis Treatment Market
14. MEA Postmenopausal Osteoporosis Treatment Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Amgen Inc.
- Eli Lilly and Company
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sanofi
- Johnson & Johnson.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 9.65 Billion |
| Forecasted Market Value ( USD | $ 17.04 Billion |
| Compound Annual Growth Rate | 5.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
